{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:42:41Z","timestamp":1759516961292,"version":"build-2065373602"},"reference-count":14,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,10,11]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:p>Talimogene laherparepvec (T-VEC) has become an increasingly popular treatment option for surgically non-resectable, recurrent melanoma, usually of cutaneous metastases. The complete response (CR) rate has been reported to be ~20% with a median of ~9 months to achieve it. In real-world practice, decrease of tumor size often occurs rapidly within the first 2\u20133 months, while improvement of the pigmentation takes several more months. Such clinical observation of lasting pigmentation could be explained by tumorous melanosis\u2014a histopathological term referring to the presence of a melanophage-rich inflammatory infiltrate without remaining viable tumor cells. Herein, we report six patients with metastatic cutaneous melanoma who were treated with T-VEC. Biopsies were performed after observing clinical responses in the injected tumors. Pathological evaluation demonstrated non-viable or absent tumor tissue with tumorous melanosis in all cases. To accurately assess response to therapy and potentially decrease unnecessary additional T-VEC treatments, serial biopsy of \u2018stable\u2019 lesions should be considered to assess the presence or absence of viable tumor.<\/jats:p>","DOI":"10.1136\/jitc-2022-005257","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T11:16:07Z","timestamp":1666955767000},"page":"e005257","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4366-1821","authenticated-orcid":false,"given":"Song Y","family":"Park","sequence":"first","affiliation":[{"name":"Division of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin R","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rouba","family":"Hadi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Billings Clinic, Billings, Montana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coley","family":"Doolittle-Amieva","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Gardner","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA"},{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ata S","family":"Moshiri","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA"},{"name":"Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA"},{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"2025100311175530000_10.10.e005257.1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2217\/imt-2019-0033","article-title":"Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety","volume":"11","author":"Raman","year":"2019","journal-title":"Immunotherapy"},{"key":"2025100311175530000_10.10.e005257.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"2025100311175530000_10.10.e005257.3","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S115245"},{"key":"2025100311175530000_10.10.e005257.4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1001\/jamadermatol.2018.5347","article-title":"Extensive pigment incontinence mimicking persistent melanoma after Talimogene Laherparepvec therapy","volume":"155","author":"Danesh","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2025100311175530000_10.10.e005257.5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jdcr.2018.01.023","article-title":"Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy","volume":"4","author":"Rizzo","year":"2018","journal-title":"JAAD Case Rep"},{"key":"2025100311175530000_10.10.e005257.6","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/CMR.0000000000000661","article-title":"Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec","volume":"30","author":"Audrey-Bayan","year":"2020","journal-title":"Melanoma Res"},{"key":"2025100311175530000_10.10.e005257.7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/bjd.14474","article-title":"Extensive tumoral melanosis associated with ipilimumab-treated melanoma","volume":"175","author":"Staser","year":"2016","journal-title":"Br J Dermatol"},{"key":"2025100311175530000_10.10.e005257.8","article-title":"Tumoral melanosis associated with Pembrolizumab-Treated metastatic melanoma","volume":"9","author":"Bari","year":"2017","journal-title":"Cureus"},{"key":"2025100311175530000_10.10.e005257.9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/DAD.0000000000001066","article-title":"Granulomatous tumoral melanosis associated with pembrolizumab therapy: a Mimicker of disease progression in metastatic melanoma","volume":"40","author":"Woodbeck","year":"2018","journal-title":"Am J Dermatopathol"},{"key":"2025100311175530000_10.10.e005257.10","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jdcr.2018.06.024","article-title":"Tumoral melanosis associated with combined BRAF\/MEK inhibition (dabrafenib\/trametinib) in metastatic melanoma","volume":"4","author":"Laino","year":"2018","journal-title":"JAAD Case Rep"},{"key":"2025100311175530000_10.10.e005257.11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/DAD.0000000000001612","article-title":"Tumoral melanosis in the setting of targeted immunotherapy for metastatic Melanoma-A single institutional experience and literature review","volume":"43","author":"Jurgens","year":"2021","journal-title":"Am J Dermatopathol"},{"key":"2025100311175530000_10.10.e005257.12","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2019.0144"},{"key":"2025100311175530000_10.10.e005257.13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41436-019-0639-2","article-title":"The pleiotropy associated with de novo variants in CHD4, CNOT3, and SETD5 extends to moyamoya angiopathy","volume":"22","author":"Pinard","year":"2020","journal-title":"Genet Med"},{"key":"2025100311175530000_10.10.e005257.14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/DAD.0000000000002174","article-title":"Tumoral melanosis and separate granulomatous inflammation due to Talimogene Laherparepvec","volume":"44","author":"Shwe","year":"2022","journal-title":"Am J Dermatopathol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005257","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:18:05Z","timestamp":1759515485000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":14,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,28]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/jitc-2022-005257"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005257","relation":{},"ISSN":["2051-1426"],"issn-type":[{"type":"electronic","value":"2051-1426"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}